Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company dedicated to the treatment and prevention of cancer. The company's core focus includes developing vaccines and therapies aimed at critical unmet needs in oncology. Anixa's innovative approach involves both diagnostics and therapeutics to detect and treat cancer at its most curable stages.
The company's therapeutic portfolio features a pioneering ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center. This program utilizes a novel CAR-T technology, known as chimeric endocrine receptor T-cell (CER-T), which targets the follicle-stimulating hormone receptor (FSHR) specifically expressed on ovarian cells. This technology represents a potential breakthrough in treating solid tumors, a challenge for traditional CAR-T therapies.
Anixa is also advancing a unique vaccine portfolio in collaboration with Cleveland Clinic, targeting the prevention of breast cancer, specifically triple-negative breast cancer (TNBC), the most aggressive form of the disease, as well as ovarian cancer. These vaccine technologies focus on immunizing against
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced the U.S. Patent and Trademark Office granted a Notice of Allowance for its Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology. The patent broadens protection for the company’s Chimeric Endocrine Receptor T-cell (CER-T) technology, specifically targeting ovarian cancer, with plans to start clinical trials before year-end. This technology, in collaboration with Moffitt Cancer Center and licensed from The Wistar Institute, holds potential for treating other solid tumors by exploiting unique hormone receptor biology.
Anixa Biosciences (NASDAQ: ANIX) announced that Dr. José Conejo-Garcia will present on September 23, 2021, at the Emerging Immunotherapeutics for Ovarian Cancer Symposium. He will discuss the FSHR-mediated CAR-T technology for ovarian cancer, which recently received FDA authorization for Phase 1 clinical trials. This technology aims to improve treatment outcomes by targeting the follicle stimulating hormone receptor on ovarian granulosa cells. Anixa holds exclusive rights to this innovative therapy, highlighting its potential to shift the treatment paradigm in ovarian cancer.
Anixa Biosciences, Inc. (NASDAQ: ANIX) will have its CEO, Dr. Amit Kumar, present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. Dr. Kumar will share insights on recent achievements, including FDA clearance for clinical trials of a CAR-T based ovarian cancer therapy and updates on breast cancer vaccine trials. Online one-on-one meetings will be available post-presentation. The event begins at 7:00 a.m. ET on September 13, 2021, with a webcast link provided for access.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced the appointment of Dr. Pamela D. Garzone as Chief Development Officer on September 7, 2021. Dr. Garzone, who has over 25 years of experience in the pharmaceutical industry, will oversee the company's vaccine and therapeutic development programs. Her role is particularly significant as Anixa prepares to enter clinical trials for its preventative breast cancer vaccine and ovarian cancer CAR-T treatment. CEO Amit Kumar expressed confidence in Dr. Garzone's leadership during this pivotal transition from pre-clinical to clinical phases.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced that its compounds may be more effective against the Delta variant of SARS-CoV-2 than the original strain. This follows a genomic variant analysis indicating stronger inhibition potential of the Mpro enzyme, crucial for viral replication. The need for affordable, stable, orally bioavailable COVID-19 treatments is emphasized due to vaccination limitations and variant efficacy concerns. The collaboration with MolGenie focuses on developing novel small molecule inhibitors, with ongoing synthesis of candidate compounds for pre-clinical testing.
Anixa Biosciences (NASDAQ: ANIX) announced the appointment of Director Dr. Arnold Baskies to the World Health Organization's Global Breast Cancer Initiative on August 23, 2021. Dr. Baskies, a seasoned surgical oncologist with extensive experience in cancer treatment, aims to strengthen global breast cancer efforts. Anixa is also developing a breast cancer vaccine in partnership with the Cleveland Clinic and the U.S. Department of Defense, which is set to enter clinical testing soon. This initiative aligns with Anixa's mission to combat cancer through innovative therapeutics.
Anixa Biosciences (NASDAQ: ANIX) announced the issuance of its first U.S. patent for an innovative ovarian cancer vaccine technology, developed in collaboration with Cleveland Clinic. The patent, titled "Ovarian Cancer Vaccines," focuses on a protein expressed in pre-menopausal women's ovaries, which is also found in ovarian cancer cells. By training the immune system to target this protein, the vaccine aims to prevent ovarian cancer's onset. The technology is already patented in Europe, and further development will be supported by the National Cancer Institute's PREVENT program.
On May 26, 2021, Anixa Biosciences (NASDAQ: ANIX) announced its ovarian cancer vaccine technology is receiving support from the National Cancer Institute (NCI). This collaboration is facilitated through the NCI-PREVENT program, which aims to develop cancer prevention interventions. Key milestones include immunogenicity testing, vaccine production development, and regulatory meetings. The vaccine technology focuses on immunizing against proteins linked to ovarian cancer, with the goal of significantly reducing its global impact. Anixa's partnership with the Cleveland Clinic enhances their capabilities in tackling cancer.
On May 20, 2021, Anixa Biosciences (NASDAQ: ANIX) announced that the U.S. FDA has detailed additional information needed for its Chimeric Antigen Receptor-T cell therapy (CAR-T) IND application, submitted in March in partnership with Moffitt Cancer Center. Anixa aims to provide the requested data within 30 days, with the FDA expected to respond in another 30 days. The CAR-T therapy targets the follicle stimulating hormone receptor, marking a novel approach in cancer treatment. Anixa is also pursuing vaccine programs for specific cancers like breast and ovarian cancer.
OntoChem GmbH has transferred its drug discovery technologies and collaborative assets with Anixa Biosciences, Inc. (NASDAQ: ANIX) to the newly established MolGenie GmbH. This transition focuses on developing an orally administered anti-viral treatment for Covid-19, leveraging data from recent studies. Anixa will collaborate with MolGenie to advance the project towards pre-clinical development, solidifying its commitment to combatting Covid-19. Leadership from both companies expresses optimism about the progress and future directions of this important partnership.
FAQ
What is the current stock price of Anixa Biosciences (ANIX)?
What is the market cap of Anixa Biosciences (ANIX)?
What does Anixa Biosciences specialize in?
What are the key components of Anixa's therapeutic portfolio?
What recent achievements has Anixa Biosciences announced?
Who are some of Anixa Biosciences' key collaborators?
How does Anixa's CER-T technology differ from traditional CAR-T therapies?
What is unique about Anixa's cancer vaccine technology?
Which forms of cancer are Anixa's vaccines targeting?
What are some recent clinical trial results from Anixa?
Does Anixa Biosciences participate in industry conferences?
Where can I find more information about Anixa Biosciences?
